Using overexpression and knockdown approaches and pharmacological inhibitors, we identify a novel molecular mechanism involving the EGFR-ProT-NF-κB-HOTAIR signaling axis in cisplatin-associated cancer cachexia in bladder cancer cells (Fig. 9). Here, EGFR is linked to urinary bladder cancer.